- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07677280
A Consumer Use Behavior Study to Measure the Puffing Topography of Heated Tobacco Products
A Consumer Use Behavior Study to Measure the Puffing Topography of Heated Tobacco Products (Glo and Glo Plus)
Přehled studie
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Montgomery Hedgecock
- Telefonní číslo: 336-741-3761
- E-mail: montgomery_hedgecock@rjrt.com
Studijní místa
-
-
-
Cheshunt, Spojené království
- Cheshunt Community Sports Park
-
Sheffield, Spojené království
- Channing Hall
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Ability to read, understand, and be willing to sign an ICF and complete questionnaires written in English.
- Generally healthy male or female, between age 21-65 years (inclusive at the time of consent), verified with government-issued identification.
- All female (assigned at birth) candidate participants and those who identify as "intersex" or "unknown" during screening who agree to take the pregnancy test on site and receive a negative result, and who affirm at the SEV that they are not pregnant or intending to become pregnant.
- Self-report currently smoking at least five CPD on smoking days in the past 30 days.
- Smoke CC on at least 27 days out of last 30 days.
- Have smoked at least 100 factory-made filtered CC in their lifetime prior to SEV.
- Indicate a willingness to use an HTP.
- Agree to participate in the study and to abide by the study restrictions and requirements, including the use of the assigned Study IP, as described in the ICF.
- Agree not to allow any other person to use any product provided to them for use during this study.
Exclusion Criteria:
- Female participants who self-report they are pregnant or breastfeeding or could become pregnant or start breastfeeding in the next 6 months from the study start date.
Women who self-report they are not intending to use adequate contraception methods to prevent pregnancy.
a) Examples of acceptable contraception methods are, but not limited to: i. Surgical sterilization (hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy, bilateral salpingectomy); ii. Established use of oral, implantable, injectable, or transdermal methods of contraception associated with inhibition of ovulation; iii. Physical barrier method (e.g., condom, diaphragm/sponge/cervical cap) with spermicide; iv. Non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs (e.g., Mirena or Kyleena); v. Vasectomized partner; vi. Abstinence from heterosexual intercourse (as a lifestyle choice, not just for the purpose of study participation); and vii. Post-menopausal who are not on hormone replacement therapy.
- Males who self-report they are not willing to use a barrier method of contraception (e.g., a condom with spermicide) or to refrain from donating sperm from the time of signing the informed consent until the EOS, unless they have undergone a vasectomy or were abstinent from heterosexual intercourse, or their female partner was not able to bear children.
- Individuals who self-report having pacemakers or other embedded electronic medical devices.
- Individuals who self-report having an unstable heart condition, severe hypertension or diabetes.
- Individuals who self-report they are sensitive to nicotine.
- Individuals who respond with 'Poor' or 'Don't know' to general physical or mental health.
- Individuals who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days.
- Individuals who are employed by a company that manufactures tobacco, HTPs, marketing or in ongoing litigation with a tobacco company.
- Individuals who self-report that they are planning to quit all nicotine products in the next three months.
- Individuals who are personally, have household members, or have close family or friends in ongoing or past litigation with a company that manufactures tobacco or HTPs.
- People who have taken part in a tobacco/nicotine research study in the past 30 days.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Jiný
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: HTP Device 1
|
Tobacco Flavor
Menthol Flavor
|
|
Experimentální: HTP Device 2
|
Tobacco Flavor
Menthol Flavor
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
To measure the puffing topography of primary CC smokers when using either the glo or glo plus device with one of two stick variants during a five-day use period.
Časové okno: 5 days
|
The primary endpoints of this study will be measured in using built-in topography measures and the product use behavior (PUB) instrument (Study Arm 1 only). The data will include:
|
5 days
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Determine the frequency of use of the glo and glo plus devices in Standard and Boost Mode
Časové okno: 5 days
|
This secondary endpoint will be measured using the built-in topography measures through the Product Use Behavior (PUB) device
|
5 days
|
|
Determine the frequency of use of the glo plus pen detached from the charger pack (Study Arm 2 only)
Časové okno: 5 days
|
This secondary endpoint will be measured using the built-in topography measures through the Product Use Behavior (PUB) device
|
5 days
|
|
Determine the average daily consumption (ADC) of CC smoked, sticks consumed, and other TNPs used
Časové okno: 5 days
|
Through self-reported questionnaires
|
5 days
|
|
Determine overall product liking and purchase intent
Časové okno: 5 days
|
Overall Product Liking: 1 (Strongly Dislike) - 10 (Strongly Like) Purchase Intent: 1 (Definitely would not purchase) - 10 (Definitely would purchase)
|
5 days
|
|
Characterize demographic characteristics
Časové okno: 5 days
|
5 days
|
|
|
Determine the safety profile (i.e., adverse events/experiences [AEs]) of the Study IP
Časové okno: 5 days
|
5 days
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Ředitel studie: Melissa Tapia, Ph.D., RAIS Company
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- PHI252503
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .